CN102850435B - 用于表达mphosph1或depdc1多肽的癌症的肽疫苗 - Google Patents

用于表达mphosph1或depdc1多肽的癌症的肽疫苗 Download PDF

Info

Publication number: CN102850435B
Authority: CN; China
Prior art keywords: peptide; cell; cancer; depdc1; seqidno
Prior art date: 2006-10-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

CN201210305732.2A

Other languages

English (en)

Chinese (zh)

Other versions

CN102850435A (zh

Inventor

藤冈知昭

中村佑辅

角田卓也

大泽龙司

志田绿

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Oncotherapy Science Inc

Original Assignee

Oncotherapy Science Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-17

Filing date

2007-10-16

Publication date

2016-02-17

2007-10-16 Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc

2013-01-02 Publication of CN102850435A publication Critical patent/CN102850435A/zh

2016-02-17 Application granted granted Critical

2016-02-17 Publication of CN102850435B publication Critical patent/CN102850435B/zh

Status Active legal-status Critical Current

2027-10-16 Anticipated expiration legal-status Critical

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 114
201000011510 cancer Diseases 0.000 title claims abstract description 89
101000950642 Homo sapiens DEP domain-containing protein 1A Proteins 0.000 title abstract description 137
229940023041 peptide vaccine Drugs 0.000 title abstract description 5
102100037691 Kinesin-like protein KIF20B Human genes 0.000 title abstract description 4
101001027631 Homo sapiens Kinesin-like protein KIF20B Proteins 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 374
210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 207
238000000034 method Methods 0.000 claims abstract description 131
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 74
229960005486 vaccine Drugs 0.000 claims abstract description 37
230000008569 process Effects 0.000 claims abstract description 36
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 24
210000004027 cell Anatomy 0.000 claims description 214
210000000612 antigen-presenting cell Anatomy 0.000 claims description 60
108010013476 HLA-A24 Antigen Proteins 0.000 claims description 48
206010005003 Bladder cancer Diseases 0.000 claims description 44
108090000623 proteins and genes Proteins 0.000 claims description 44
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 42
201000005112 urinary bladder cancer Diseases 0.000 claims description 41
239000000427 antigen Substances 0.000 claims description 39
108091007433 antigens Proteins 0.000 claims description 39
102000036639 antigens Human genes 0.000 claims description 39
238000011282 treatment Methods 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 36
230000001939 inductive effect Effects 0.000 claims description 31
210000001744 T-lymphocyte Anatomy 0.000 claims description 29
230000006698 induction Effects 0.000 claims description 28
206010025323 Lymphomas Diseases 0.000 claims description 27
206010006187 Breast cancer Diseases 0.000 claims description 25
208000026310 Breast neoplasm Diseases 0.000 claims description 25
206010008342 Cervix carcinoma Diseases 0.000 claims description 25
208000000236 Prostatic Neoplasms Diseases 0.000 claims description 25
208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 25
201000010881 cervical cancer Diseases 0.000 claims description 25
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 24
208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 24
208000001333 Colorectal Neoplasms Diseases 0.000 claims description 24
206010068771 Soft tissue neoplasm Diseases 0.000 claims description 24
208000006990 cholangiocarcinoma Diseases 0.000 claims description 24
208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 24
208000005718 Stomach Neoplasms Diseases 0.000 claims description 22
206010060862 Prostate cancer Diseases 0.000 claims description 21
206010041067 Small cell lung cancer Diseases 0.000 claims description 21
210000003734 kidney Anatomy 0.000 claims description 21
201000008968 osteosarcoma Diseases 0.000 claims description 21
229920001184 polypeptide Polymers 0.000 claims description 21
201000000498 stomach carcinoma Diseases 0.000 claims description 21
206010009944 Colon cancer Diseases 0.000 claims description 20
201000010989 colorectal carcinoma Diseases 0.000 claims description 19
230000002163 immunogen Effects 0.000 claims description 17
210000001808 exosome Anatomy 0.000 claims description 16
108020004707 nucleic acids Proteins 0.000 claims description 11
102000039446 nucleic acids Human genes 0.000 claims description 11
150000007523 nucleic acids Chemical class 0.000 claims description 11
230000002265 prevention Effects 0.000 claims description 11
238000000338 in vitro Methods 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 7
238000000926 separation method Methods 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
108091033319 polynucleotide Proteins 0.000 claims description 5
102000040430 polynucleotide Human genes 0.000 claims description 5
239000002157 polynucleotide Substances 0.000 claims description 5
230000009977 dual effect Effects 0.000 claims description 2
101150090724 3 gene Proteins 0.000 claims 1
101150096316 5 gene Proteins 0.000 claims 1
230000007541 cellular toxicity Effects 0.000 claims 1
102100037753 DEP domain-containing protein 1A Human genes 0.000 abstract description 127
235000001014 amino acid Nutrition 0.000 abstract description 53
150000001413 amino acids Chemical class 0.000 abstract description 51
201000010099 disease Diseases 0.000 abstract description 43
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 43
239000003814 drug Substances 0.000 abstract description 13
230000008034 disappearance Effects 0.000 abstract description 5
230000000694 effects Effects 0.000 description 102
102100037850 Interferon gamma Human genes 0.000 description 69
108010074328 Interferon-gamma Proteins 0.000 description 69
229940024606 amino acid Drugs 0.000 description 52
230000014509 gene expression Effects 0.000 description 46
108010075704 HLA-A Antigens Proteins 0.000 description 37
102000011786 HLA-A Antigens Human genes 0.000 description 37
230000004044 response Effects 0.000 description 35
238000001890 transfection Methods 0.000 description 35
101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 28
239000000463 material Substances 0.000 description 25
210000004443 dendritic cell Anatomy 0.000 description 24
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 21
108010088729 HLA-A*02:01 antigen Proteins 0.000 description 18
210000004881 tumor cell Anatomy 0.000 description 18
235000018102 proteins Nutrition 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 17
238000011081 inoculation Methods 0.000 description 16
238000012360 testing method Methods 0.000 description 15
241000699666 Mus <mouse, genus> Species 0.000 description 14
230000000259 anti-tumor effect Effects 0.000 description 13
230000009471 action Effects 0.000 description 12
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
239000002671 adjuvant Substances 0.000 description 11
230000000118 anti-neoplastic effect Effects 0.000 description 11
238000010790 dilution Methods 0.000 description 11
239000012895 dilution Substances 0.000 description 11
230000000670 limiting effect Effects 0.000 description 11
238000001727 in vivo Methods 0.000 description 10
238000011725 BALB/c mouse Methods 0.000 description 9
238000011510 Elispot assay Methods 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
230000001472 cytotoxic effect Effects 0.000 description 9
238000009169 immunotherapy Methods 0.000 description 9
230000004913 activation Effects 0.000 description 8
230000001900 immune effect Effects 0.000 description 8
238000012216 screening Methods 0.000 description 8
230000000638 stimulation Effects 0.000 description 8
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 7
239000012634 fragment Substances 0.000 description 7
230000006870 function Effects 0.000 description 7
229960004452 methionine Drugs 0.000 description 7
229930182817 methionine Natural products 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
210000004988 splenocyte Anatomy 0.000 description 7
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
230000030741 antigen processing and presentation Effects 0.000 description 6
230000001413 cellular effect Effects 0.000 description 6
238000011156 evaluation Methods 0.000 description 6
230000005847 immunogenicity Effects 0.000 description 6
229960003136 leucine Drugs 0.000 description 6
239000000047 product Substances 0.000 description 6
238000010254 subcutaneous injection Methods 0.000 description 6
239000007929 subcutaneous injection Substances 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
239000013598 vector Substances 0.000 description 6
206010070834 Sensitisation Diseases 0.000 description 5
230000003321 amplification Effects 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
238000005516 engineering process Methods 0.000 description 5
230000012010 growth Effects 0.000 description 5
230000036039 immunity Effects 0.000 description 5
230000003116 impacting effect Effects 0.000 description 5
238000003199 nucleic acid amplification method Methods 0.000 description 5
238000012797 qualification Methods 0.000 description 5
230000008313 sensitization Effects 0.000 description 5
238000012546 transfer Methods 0.000 description 5
238000002255 vaccination Methods 0.000 description 5
101100162703 Caenorhabditis elegans ani-1 gene Proteins 0.000 description 4
101150054188 DEPDC1 gene Proteins 0.000 description 4
102000017944 Dishevelled Human genes 0.000 description 4
108050007016 Dishevelled Proteins 0.000 description 4
102000010638 Kinesin Human genes 0.000 description 4
108010063296 Kinesin Proteins 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
241001582888 Lobus Species 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
108700020796 Oncogene Proteins 0.000 description 4
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
239000006035 Tryptophane Substances 0.000 description 4
241000700605 Viruses Species 0.000 description 4
230000005809 anti-tumor immunity Effects 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
238000012790 confirmation Methods 0.000 description 4
231100000433 cytotoxic Toxicity 0.000 description 4
238000011161 development Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000007794 irritation Effects 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
230000001394 metastastic effect Effects 0.000 description 4
206010061289 metastatic neoplasm Diseases 0.000 description 4
239000013642 negative control Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
229960005190 phenylalanine Drugs 0.000 description 4
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
230000004936 stimulating effect Effects 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
229960004799 tryptophan Drugs 0.000 description 4
108020004414 DNA Proteins 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
230000005975 antitumor immune response Effects 0.000 description 3
201000001531 bladder carcinoma Diseases 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
230000009849 deactivation Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000007689 inspection Methods 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000036961 partial effect Effects 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
206010037844 rash Diseases 0.000 description 3
238000011160 research Methods 0.000 description 3
238000011255 standard chemotherapy Methods 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
208000010570 urinary bladder carcinoma Diseases 0.000 description 3
VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 description 2
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
101100011364 Caenorhabditis elegans egl-10 gene Proteins 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
208000010201 Exanthema Diseases 0.000 description 2
241001489120 Kondoa Species 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
102100030264 Pleckstrin Human genes 0.000 description 2
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
229940037003 alum Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
238000009566 cancer vaccine Methods 0.000 description 2
229940022399 cancer vaccine Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000013399 edible fruits Nutrition 0.000 description 2
238000004945 emulsification Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
230000000763 evoking effect Effects 0.000 description 2
201000005884 exanthem Diseases 0.000 description 2
238000012637 gene transfection Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000004068 intracellular signaling Effects 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
230000002147 killing effect Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000002493 microarray Methods 0.000 description 2
238000012775 microarray technology Methods 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
239000012071 phase Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
108010026735 platelet protein P47 Proteins 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001177 retroviral effect Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000004088 simulation Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
230000016853 telophase Effects 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000002103 transcriptional effect Effects 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
229960004441 tyrosine Drugs 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
241001227713 Chiron Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
238000000018 DNA microarray Methods 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
101150029707 ERBB2 gene Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000000666 Fowlpox Diseases 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
108050007394 Kinesin-like protein KIF20B Proteins 0.000 description 1
108010059881 Lactase Proteins 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010027458 Metastases to lung Diseases 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
241000009328 Perro Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
206010040914 Skin reaction Diseases 0.000 description 1
108020004459 Small interfering RNA Proteins 0.000 description 1
235000018259 Solanum vestissimum Nutrition 0.000 description 1
240000002825 Solanum vestissimum Species 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000006229 amino acid addition Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
239000012984 antibiotic solution Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
244000309466 calf Species 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
230000003327 cancerostatic effect Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
-1 cationic lipid Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000005336 cracking Methods 0.000 description 1
239000012531 culture fluid Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000003113 dilution method Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000004043 dyeing Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
210000000222 eosinocyte Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000006052 feed supplement Substances 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
238000011223 gene expression profiling Methods 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
210000002360 granulocyte-macrophage progenitor cell Anatomy 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003118 histopathologic effect Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
238000002991 immunohistochemical analysis Methods 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
229940116108 lactase Drugs 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000003908 liver function Effects 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000000693 micelle Substances 0.000 description 1
238000012737 microarray-based gene expression Methods 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000003003 monocyte-macrophage precursor cell Anatomy 0.000 description 1
210000002433 mononuclear leukocyte Anatomy 0.000 description 1
238000012243 multiplex automated genomic engineering Methods 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000009862 primary prevention Effects 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
XZKQVQKUZMAADP-UHFFFAOYSA-N serinyl-serine Chemical compound OCC(N)C(=O)NC(CO)C(O)=O XZKQVQKUZMAADP-UHFFFAOYSA-N 0.000 description 1
230000035483 skin reaction Effects 0.000 description 1
231100000430 skin reaction Toxicity 0.000 description 1
210000004872 soft tissue Anatomy 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000000015 thermotherapy Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Cell Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Reproductive Health (AREA)
Physics & Mathematics (AREA)
Dispersion Chemistry (AREA)
Hematology (AREA)
Endocrinology (AREA)
Plant Pathology (AREA)

CN201210305732.2A 2006-10-17 2007-10-16 用于表达mphosph1或depdc1多肽的癌症的肽疫苗 Active CN102850435B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US85257506P	2006-10-17	2006-10-17
US60/852,575		2006-10-17
CN2007800467286A CN101568550B (zh)	2006-10-17	2007-10-16	用于表达mphosph1或depdc1多肽的癌症的肽疫苗

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CN2007800467286A Division CN101568550B (zh)	2006-10-17	2007-10-16	用于表达mphosph1或depdc1多肽的癌症的肽疫苗

Publications (2)

Publication Number	Publication Date
CN102850435A CN102850435A (zh)	2013-01-02
CN102850435B true CN102850435B (zh)	2016-02-17

Family

ID=39313729

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
CN201210305732.2A Active CN102850435B (zh)	2006-10-17	2007-10-16	用于表达mphosph1或depdc1多肽的癌症的肽疫苗
CN201210305207.0A Active CN102850433B (zh)	2006-10-17	2007-10-16	用于表达mphosph1或depdc1多肽的癌症的肽疫苗
CN201210305211.7A Active CN102850434B (zh)	2006-10-17	2007-10-16	用于表达mphosph1或depdc1多肽的癌症的肽疫苗
CN2007800467286A Active CN101568550B (zh)	2006-10-17	2007-10-16	用于表达mphosph1或depdc1多肽的癌症的肽疫苗
CN201610069574.3A Pending CN105693843A (zh)	2006-10-17	2007-10-16	用于表达mphosph1或depdc1多肽的癌症的肽疫苗

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
CN201210305207.0A Active CN102850433B (zh)	2006-10-17	2007-10-16	用于表达mphosph1或depdc1多肽的癌症的肽疫苗
CN201210305211.7A Active CN102850434B (zh)	2006-10-17	2007-10-16	用于表达mphosph1或depdc1多肽的癌症的肽疫苗
CN2007800467286A Active CN101568550B (zh)	2006-10-17	2007-10-16	用于表达mphosph1或depdc1多肽的癌症的肽疫苗
CN201610069574.3A Pending CN105693843A (zh)	2006-10-17	2007-10-16	用于表达mphosph1或depdc1多肽的癌症的肽疫苗

Country Status (18)

Country	Link
US (5)	US8557955B2 (xx)
EP (7)	EP2476699B1 (xx)
JP (2)	JP5339292B2 (xx)
KR (4)	KR101527473B1 (xx)
CN (5)	CN102850435B (xx)
AU (1)	AU2007311395B2 (xx)
BR (1)	BRPI0717651A2 (xx)
CA (2)	CA2667030C (xx)
DK (1)	DK2091965T3 (xx)
ES (4)	ES2415958T3 (xx)
HK (4)	HK1171026A1 (xx)
IL (4)	IL198186A (xx)
MX (1)	MX2009004147A (xx)
PL (1)	PL2091965T3 (xx)
PT (1)	PT2091965E (xx)
RU (1)	RU2469044C2 (xx)
SG (2)	SG10201502098YA (xx)
WO (1)	WO2008047473A1 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2011885B1 (en)	2005-02-10	2015-04-22	Oncotherapy Science, Inc.	Method of diagnosing bladder cancer
CA2696591C (en) *	2007-08-20	2016-10-11	Oncotherapy Science, Inc.	Cdh3 peptide and medicinal agent comprising the same
WO2010023850A1 (en) *	2008-08-28	2010-03-04	Oncotherapy Science, Inc.	Method for treating or preventing bladder cancer using the depdc1 polypeptide
US20120107333A1 (en) *	2009-03-04	2012-05-03	Oncotherapy Science, Inc.	Vangl1 peptides and vaccines including the same
WO2012032763A1 (en) *	2010-09-07	2012-03-15	Oncotherapy Science, Inc.	Vangl1 peptides and vaccines including the same
AU2012296090B2 (en)	2011-08-12	2015-05-14	Oncotherapy Science, Inc.	MPHOSPH1 peptides and vaccines including the same
JP2013058294A (ja) *	2011-09-09	2013-03-28	Toshiba Corp	磁気記録媒体及び磁気記録媒体の製造方法
SG10201606970UA (en)	2012-02-23	2016-10-28	Juno Therapeutics Gmbh	Chromatographic isolation of cells and other complex biological materials
US20150359864A1 (en) *	2012-03-09	2015-12-17	Oncotherapy Science, Inc.	Pharmaceutical composition containing peptides
JP6041297B2 (ja) *	2012-08-24	2016-12-07	国立大学法人山口大学	犬リンパ腫の診断方法及び診断キット
JP6250631B2 (ja) *	2013-03-13	2017-12-20	忠李	微小胞及びその製造方法
PL3132247T3 (pl)	2014-04-16	2022-01-03	Juno Therapeutics Gmbh	Sposoby, zestawy i urządzenie do namnażania populacji komórek
WO2016056596A1 (ja)	2014-10-07	2016-04-14	日本電気株式会社	Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
US20180200325A1 (en) *	2014-11-18	2018-07-19	Shionogi & Co., Ltd.	Stabilized peptide composition
WO2016143816A1 (ja)	2015-03-09	2016-09-15	日本電気株式会社	Ｇｐｃ３由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
CN107530432B (zh)	2015-04-07	2021-04-27	Cytlimic公司	药物
CN108138170B (zh) *	2015-08-12	2022-01-25	肿瘤疗法科学股份有限公司	Depdc1衍生的肽和包含它们的疫苗
CN108699111B (zh) *	2015-10-08	2022-11-01	肿瘤疗法科学股份有限公司	Mphosph1衍生的肽和包含它们的疫苗
MA45488A (fr)	2015-10-22	2018-08-29	Juno Therapeutics Gmbh	Procédés, kits et appareil de culture de cellules
MA45489A (fr)	2015-10-22	2018-08-29	Juno Therapeutics Gmbh	Procédés de culture de cellules, kits et appareil associés
RU2021134624A (ru)	2015-10-22	2022-03-15	Джуно Терапьютикс Гмбх	Способы, наборы, средства и устройства для трансдукции
WO2018070069A1 (ja)	2016-10-11	2018-04-19	サイトリミック株式会社	医薬
JP2020501524A (ja) *	2016-11-18	2020-01-23	オンコセラピー・サイエンス株式会社	Ｔｈ１細胞のためのＭＰＨＯＳＰＨ１エピトープペプチドおよびこれを含有するワクチン
WO2018092754A1 (en) *	2016-11-18	2018-05-24	Oncotherapy Science, Inc.	Depdc1 epitope peptides for th1 cells and vaccines containing the same
CN109923121B (zh) *	2016-11-22	2022-12-23	武汉华大吉诺因生物科技有限公司	多肽及其应用
RS63259B1 (sr)	2017-01-25	2022-06-30	Ose Immunotherapeutics	Postupak za proizvodnju stabilne emulzije za isporuku peptida
EP3615653A1 (en)	2017-04-27	2020-03-04	Juno Therapeutics GmbH	Oligomeric particle reagents and methods of use thereof
KR102709778B1 (ko) *	2017-07-12	2024-09-26	노우스콤 아게	미세부수체 불안정성(msi) 암의 예방 및 치료를 위한 공유된 종양 신생항원을 기반으로 한 범용 백신
BR112020011620A2 (pt) *	2017-12-13	2020-12-08	Inovio Pharmaceuticals, Inc.	Vacinas de câncer com alvo lemd1 e usos das mesmas
CN109932510B (zh) *	2017-12-18	2022-07-12	天津云检医学检验所有限公司	一种宫颈癌生物标志物及其检测试剂盒
CN112142824B (zh) *	2019-06-27	2022-03-11	深圳市东贵博康生化科技有限公司	具有诱导细胞毒性t淋巴细胞能力的多肽及其应用
WO2021060343A1 (ja) *	2019-09-24	2021-04-01	オンコセラピー・サイエンス株式会社	Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006085684A2 (en) *	2005-02-10	2006-08-17	Oncotherapy Science, Inc.	Method of diagnosing bladder cancer

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
RU94038427A (ru)	1991-08-26	1996-10-20	Сайтел Корпорейшн (US)	Пептиды, конъюгаты, фармацевтические композиции, способы лечения, способ идентификации
DE69231621T2 (de)	1991-08-26	2001-05-31	Epimmune, Inc.	Hepatitis-B-Virus-Epitope mit HLA-reduzierte CTL-Respons
CN1122576A (zh) *	1993-03-11	1996-05-15	南加利福尼亚大学	免疫感染簇病毒感染的治疗策略
US5804566A (en)	1993-08-26	1998-09-08	The Regents Of The University Of California	Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en)	1993-08-26	1997-10-21	The Regents Of The University Of California	Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en)	1994-04-01	1998-04-14	Apollon, Inc.	Compositions and methods for delivery of genetic material
US5736524A (en)	1994-11-14	1998-04-07	Merck & Co.,. Inc.	Polynucleotide tuberculosis vaccine
US5922687A (en)	1995-05-04	1999-07-13	Board Of Trustees Of The Leland Stanford Junior University	Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en)	1995-08-03	2003-10-23	Johannes J. Geuze	Cell derived antigen presenting vesicles
US5853719A (en)	1996-04-30	1998-12-29	Duke University	Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
WO1998004720A1 (en)	1996-07-26	1998-02-05	Sloan-Kettering Institute For Cancer Research	Method and reagents for genetic immunization
FR2766205B1 (fr)	1997-07-16	2002-08-30	Inst Nat Sante Rech Med	Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7001999B1 (en)	1998-04-15	2006-02-21	Ludwig Institute For Cancer Research	Tumor associated nucleic acids and uses therefor
PL201881B1 (pl) *	1998-09-30	2009-05-29	Corixa Corp	Izolowany polipeptyd składający się z immunogennej części natywnego WT1, zawierająca go kompozycja farmaceutyczna i szczepionka oraz polinukleotyd kodujący ten polipeptyd
US20050123938A1 (en)	1999-01-06	2005-06-09	Chondrogene Limited	Method for the detection of osteoarthritis related gene transcripts in blood
US20040241726A1 (en)	1999-01-06	2004-12-02	Chondrogene Limited	Method for the detection of allergies related gene transcripts in blood
US6291663B1 (en)	1999-03-03	2001-09-18	Board Of Trustees Of The University Of Arkansas	TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US7030215B2 (en) *	1999-03-24	2006-04-18	Sangamo Biosciences, Inc.	Position dependent recognition of GNN nucleotide triplets by zinc fingers
EP1259812A2 (en) *	1999-05-28	2002-11-27	Ludwig Institute For Cancer Research	Breast, gastric and prostate cancer associated antigens and uses therefor
US20030166526A1 (en)	2000-08-22	2003-09-04	Challita-Eid Pia M.	Nucleic acid and corresponding protein named 158P1H4 useful in the treatment and detection of bladder and other cancers
EP1325120A4 (en)	2000-10-12	2005-05-25	Nuvelo Inc	NUCLEIC ACIDS AND POLYPEPTIDES
AU2001298049A1 (en) *	2000-10-19	2003-05-19	Epimmune Inc.	Hla class i and ii binding peptides and their uses
EP1356048A2 (en) *	2000-12-04	2003-10-29	Argonex Pharmaceuticals	Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7919467B2 (en)	2000-12-04	2011-04-05	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040142325A1 (en)	2001-09-14	2004-07-22	Liat Mintz	Methods and systems for annotating biomolecular sequences
JP2005515779A (ja) *	2002-01-31	2005-06-02	ワイス	アグレカナーゼ分子
AU2003222103A1 (en)	2002-03-28	2003-10-13	Idec Pharmaceuticals Corporation	Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20060024692A1 (en)	2002-09-30	2006-02-02	Oncotherapy Science, Inc.	Method for diagnosing non-small cell lung cancers
TW200413725A (en)	2002-09-30	2004-08-01	Oncotherapy Science Inc	Method for diagnosing non-small cell lung cancers
WO2005007090A2 (en)	2003-07-03	2005-01-27	President And Fellows Of Harvard College	Inhibitors of the map kinase pathway
WO2006031221A1 (en)	2004-09-13	2006-03-23	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Compositions comprising t cell receptors and methods of use thereof
JP2006302684A (ja)	2005-04-21	2006-11-02	D D K Ltd	カードコネクタ
US20090317392A1 (en)	2005-07-27	2009-12-24	Yusuke Nakamura	Method of diagnosing small cell lung cancer
CN101287831B (zh)	2005-09-13	2013-05-15	国立大学法人三重大学	T细胞受体和编码该受体的核酸
WO2007047796A2 (en)	2005-10-17	2007-04-26	Institute For Systems Biology	Tissue-and serum-derived glycoproteins and methods of their use
TWM336439U (en) *	2008-02-14	2008-07-11	Optivision Technology Inc	Diffuser capable of light condensing
WO2010023850A1 (en)	2008-08-28	2010-03-04	Oncotherapy Science, Inc.	Method for treating or preventing bladder cancer using the depdc1 polypeptide
AU2012296090B2 (en)	2011-08-12	2015-05-14	Oncotherapy Science, Inc.	MPHOSPH1 peptides and vaccines including the same

2007
- 2007-10-16 JP JP2009516776A patent/JP5339292B2/ja active Active
- 2007-10-16 KR KR1020157000123A patent/KR101527473B1/ko active IP Right Grant
- 2007-10-16 EP EP12155448.9A patent/EP2476699B1/en active Active
- 2007-10-16 US US12/445,729 patent/US8557955B2/en active Active
- 2007-10-16 BR BRPI0717651-1A2A patent/BRPI0717651A2/pt not_active IP Right Cessation
- 2007-10-16 EP EP20130189400 patent/EP2695895A1/en not_active Withdrawn
- 2007-10-16 PT PT78279015T patent/PT2091965E/pt unknown
- 2007-10-16 PL PL07827901T patent/PL2091965T3/pl unknown
- 2007-10-16 CN CN201210305732.2A patent/CN102850435B/zh active Active
- 2007-10-16 CN CN201210305207.0A patent/CN102850433B/zh active Active
- 2007-10-16 SG SG10201502098YA patent/SG10201502098YA/en unknown
- 2007-10-16 RU RU2009118432/10A patent/RU2469044C2/ru not_active IP Right Cessation
- 2007-10-16 CN CN201210305211.7A patent/CN102850434B/zh active Active
- 2007-10-16 DK DK07827901.5T patent/DK2091965T3/da active
- 2007-10-16 ES ES07827901T patent/ES2415958T3/es active Active
- 2007-10-16 EP EP20130189390 patent/EP2687540A1/en not_active Withdrawn
- 2007-10-16 KR KR1020097010056A patent/KR101454287B1/ko active IP Right Grant
- 2007-10-16 KR KR1020147022451A patent/KR101543622B1/ko active IP Right Grant
- 2007-10-16 ES ES12155446.3T patent/ES2545818T3/es active Active
- 2007-10-16 ES ES12155448.9T patent/ES2545457T3/es active Active
- 2007-10-16 EP EP07827901.5A patent/EP2091965B9/en active Active
- 2007-10-16 EP EP20130189408 patent/EP2687541A1/en not_active Withdrawn
- 2007-10-16 AU AU2007311395A patent/AU2007311395B2/en not_active Ceased
- 2007-10-16 CA CA2667030A patent/CA2667030C/en not_active Expired - Fee Related
- 2007-10-16 CN CN2007800467286A patent/CN101568550B/zh active Active
- 2007-10-16 SG SG2011070455A patent/SG175566A1/en unknown
- 2007-10-16 EP EP12155446.3A patent/EP2476698B1/en active Active
- 2007-10-16 EP EP12155444.8A patent/EP2476697B1/en active Active
- 2007-10-16 CA CA2915560A patent/CA2915560A1/en not_active Abandoned
- 2007-10-16 KR KR1020147011020A patent/KR101493773B1/ko active IP Right Grant
- 2007-10-16 ES ES12155444.8T patent/ES2545817T3/es active Active
- 2007-10-16 MX MX2009004147A patent/MX2009004147A/es active IP Right Grant
- 2007-10-16 CN CN201610069574.3A patent/CN105693843A/zh active Pending
- 2007-10-16 WO PCT/JP2007/001122 patent/WO2008047473A1/en active Application Filing
2009
- 2009-04-16 IL IL198186A patent/IL198186A/en not_active IP Right Cessation
- 2009-11-23 HK HK12111316.0A patent/HK1171026A1/xx not_active IP Right Cessation
- 2009-11-23 HK HK12111314.2A patent/HK1171024A1/xx not_active IP Right Cessation
- 2009-11-23 HK HK12111315.1A patent/HK1171025A1/xx not_active IP Right Cessation
- 2009-11-23 HK HK09110942.9A patent/HK1131169A1/xx not_active IP Right Cessation
2011
- 2011-12-01 IL IL216713A patent/IL216713A0/en unknown
- 2011-12-01 IL IL216712A patent/IL216712A/en not_active IP Right Cessation
2012
- 2012-06-27 US US13/535,297 patent/US9017688B2/en active Active
- 2012-06-27 US US13/535,303 patent/US8653234B2/en active Active
- 2012-07-30 US US13/562,250 patent/US8552146B2/en active Active
- 2012-11-08 IL IL222925A patent/IL222925A0/en unknown
2013
- 2013-01-18 JP JP2013006870A patent/JP2013116115A/ja active Pending
2015
- 2015-03-24 US US14/667,560 patent/US9545437B2/en active Active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006085684A2 (en) *	2005-02-10	2006-08-17	Oncotherapy Science, Inc.	Method of diagnosing bladder cancer

Also Published As

Publication number	Publication date
IL216712A (en)	2017-07-31
EP2476698A2 (en)	2012-07-18
EP2091965A4 (en)	2011-02-16
KR101454287B1 (ko)	2014-11-04
CN102850433A (zh)	2013-01-02
US8552146B2 (en)	2013-10-08
ES2415958T3 (es)	2013-07-29
WO2008047473A1 (en)	2008-04-24
KR20140104057A (ko)	2014-08-27
IL216712A0 (en)	2012-01-31
ES2545457T3 (es)	2015-09-11
CA2667030C (en)	2016-03-15
HK1171024A1 (en)	2013-03-15
AU2007311395B2 (en)	2013-02-21
IL216713A0 (en)	2012-01-31
EP2687540A1 (en)	2014-01-22
EP2476697A3 (en)	2013-11-27
KR101527473B1 (ko)	2015-06-17
HK1171025A1 (en)	2013-03-15
KR101493773B1 (ko)	2015-03-03
CN102850433B (zh)	2016-03-02
MX2009004147A (es)	2009-06-15
JP2010506826A (ja)	2010-03-04
US9017688B2 (en)	2015-04-28
RU2009118432A (ru)	2010-11-27
EP2476699A3 (en)	2013-11-27
CA2915560A1 (en)	2008-04-24
ES2545817T3 (es)	2015-09-16
AU2007311395A1 (en)	2008-04-24
CN101568550B (zh)	2012-12-26
US20150231222A1 (en)	2015-08-20
CN102850434B (zh)	2016-04-13
CN102850434A (zh)	2013-01-02
BRPI0717651A2 (pt)	2013-12-24
US20130129759A1 (en)	2013-05-23
IL222925A0 (en)	2012-12-31
IL198186A0 (en)	2011-08-01
HK1171026A1 (en)	2013-03-15
KR20140057681A (ko)	2014-05-13
KR101543622B1 (ko)	2015-08-11
EP2091965B9 (en)	2013-09-25
EP2695895A1 (en)	2014-02-12
EP2476699A2 (en)	2012-07-18
US8653234B2 (en)	2014-02-18
EP2091965A1 (en)	2009-08-26
EP2476697A2 (en)	2012-07-18
DK2091965T3 (da)	2013-08-05
JP5339292B2 (ja)	2013-11-13
US8557955B2 (en)	2013-10-15
IL198186A (en)	2017-05-29
EP2687541A1 (en)	2014-01-22
CA2667030A1 (en)	2008-04-24
SG10201502098YA (en)	2015-05-28
EP2476699B1 (en)	2015-06-17
EP2476698A3 (en)	2013-11-27
EP2476698B1 (en)	2015-06-17
ES2545818T3 (es)	2015-09-16
KR20150015042A (ko)	2015-02-09
US20100028373A1 (en)	2010-02-04
CN101568550A (zh)	2009-10-28
PL2091965T3 (pl)	2013-10-31
KR20090083378A (ko)	2009-08-03
US9545437B2 (en)	2017-01-17
CN105693843A (zh)	2016-06-22
SG175566A1 (en)	2011-11-28
PT2091965E (pt)	2013-06-11
EP2091965B1 (en)	2013-05-15
CN102850435A (zh)	2013-01-02
JP2013116115A (ja)	2013-06-13
US20120282286A1 (en)	2012-11-08
RU2469044C2 (ru)	2012-12-10
US20120288514A1 (en)	2012-11-15
HK1131169A1 (en)	2010-01-15
EP2476697B1 (en)	2015-06-17

Publication	Publication Date	Title
CN102850435B (zh)	2016-02-17	用于表达mphosph1或depdc1多肽的癌症的肽疫苗
CN102863514B (zh)	2014-12-10	用于表达肿瘤相关抗原的癌症的肽疫苗
CN101641369B (zh)	2014-10-22	Foxp3肽疫苗

Legal Events

Date	Code	Title
2013-01-02	C06	Publication
2013-01-02	PB01	Publication
2013-02-20	C10	Entry into substantive examination
2013-02-20	SE01	Entry into force of request for substantive examination
2016-02-17	C14	Grant of patent or utility model
2016-02-17	GR01	Patent grant